Open AccessHealth Care Resource Utilization and Costs in First-Line Treatments for Patients with Metastatic Melanoma in the United States
Author(s) -
Andrew J. Klink,
Bartosz Chmielowski,
Bruce A. Feinberg,
Sama Ahsan,
Damion Nero,
Frank Xiaoqing Liu
Publication year - 2019
Publication title -
journal of managed care and specialty pharmacy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.126
H-Index - 63
eISSN - 2376-1032
pISSN - 2376-0540
DOI - 10.18553/jmcp.2019.18442
Subject(s) - medicine , oncology , metastatic melanoma , odds ratio , melanoma , pharmacy , retrospective cohort study , chemotherapy , cancer , family medicine , cancer research
The treatment landscape for patients with metastatic melanoma has changed dramatically with the introduction of novel therapies, such as targeted therapies and immunotherapies, in recent years. Health care resource utilization (HCRU) and cost data are needed to further evaluate these treatments in a value-based health care system.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom